Headquarters: Cambridge, Massachusetts, U.S.
Offering: Leqembi (Lecanemab) – Amyloid Beta-directed Antibody
Case Study
Biogen Inc., a leading biotechnology company specializing in neurodegenerative and rare diseases, achieved a breakthrough in Alzheimer’s therapeutics through the global expansion of Leqembi (Lecanemab), its amyloid beta-directed antibody developed in collaboration with Eisai Co., Ltd. Following full approval by the U.S. Food and Drug Administration (FDA) in 2023, 2025 marked the year when Leqembi gained widespread reimbursement support from the Centers for Medicare & Medicaid Services (CMS) in the United States and received conditional approvals across Japan, the European Union, and select Asia-Pacific markets.
This expansion represented a pivotal step toward making disease-modifying therapies accessible to patients worldwide. Biogen’s strategic collaboration with Eisai focused on not only regulatory expansion but also real-world deployment, addressing key logistical and operational challenges that had previously limited patient access to monoclonal antibody treatments.
To ensure the therapy’s success beyond clinical settings, Biogen and Eisai introduced an integrated Digital Patient Monitoring (DPM) platform that connected infusion centers, clinicians, and caregivers in real time. This system allowed continuous tracking of patient progress, early detection of potential side effects such as amyloid-related imaging abnormalities (ARIA), and optimized dosing schedules. By 2025, over 250 infusion centers in North America and Europe were onboarded to the platform, allowing seamless coordination between neurologists, imaging centers, and patient support teams.
Leqembi’s mechanism of action involves targeting soluble and insoluble amyloid-beta aggregates in the brain — believed to be one of the primary pathological hallmarks of Alzheimer’s disease. The therapy’s Phase 3 CLARITY-AD trial results had already demonstrated statistically significant benefits, slowing the rate of cognitive and functional decline by 27% compared to placebo over 18 months. Building on these results, Biogen’s real-world evidence collection initiative in 2025 further validated the drug’s long-term benefits in diverse patient populations, including underrepresented ethnic groups and those with early-stage Alzheimer’s.
The company’s commercial strategy emphasized patient-centric delivery, including the setup of Leqembi Care Hubs — specialized treatment centers designed to streamline patient onboarding, insurance approvals, and infusion scheduling. Additionally, Biogen launched educational campaigns for healthcare providers, aimed at improving diagnostic accuracy and encouraging early intervention, since Leqembi demonstrated the greatest efficacy in patients with mild cognitive impairment (MCI) or early symptomatic Alzheimer’s.
Outcome
By the end of 2025, Biogen’s initiatives had significantly transformed the Alzheimer’s treatment landscape:
Accelerated Global Access: Leqembi was made available in over 15 countries, including the U.S., Japan, Germany, France, and Australia, within 18 months of CMS reimbursement approval. This rapid expansion was made possible by Biogen’s coordinated global regulatory strategy and Eisai’s established distribution networks.
Clinical and Real-World Impact: The drug’s post-approval studies confirmed a 27% reduction in the rate of Alzheimer’s progression, consistent with clinical trial outcomes. Moreover, Biogen’s real-world data analysis indicated a 10% increase in patient retention and a significant improvement in daily functional abilities, including memory recall and language processing, among early-stage patients.
Improved Patient Adherence: Through the AI-driven digital follow-up system, Biogen achieved over 80% therapy adherence, an impressive metric in neurodegenerative care. This was supported by automated reminders, virtual nurse check-ins, and easy access to cognitive assessment tools integrated within the patient portal.
The outcome reflected not only clinical efficacy but also successful operational execution bridging the long-standing gap between drug approval and patient accessibility in Alzheimer’s therapeutics.
Protectional
Biogen prioritized patient safety and data integrity as the foundation of its global rollout. Recognizing the complexity of monoclonal antibody therapies, the company implemented a robust AI-driven pharmacovigilance platform capable of analyzing real-time patient data from hospitals and imaging centers.
This system employed machine learning algorithms to identify early warning signs of amyloid-related imaging abnormalities (ARIA) — one of the known risks associated with anti-amyloid treatments — before clinical symptoms appeared. The platform provided healthcare professionals with proactive alerts, guiding dose modifications and minimizing hospitalization risks.
Moreover, Biogen maintained strict compliance with HIPAA, GDPR, and Japan’s Act on the Protection of Personal Information (APPI) to safeguard patient data privacy. The secure cloud infrastructure used end-to-end encryption and anonymized data models, ensuring that global post-marketing surveillance could be conducted safely and transparently.
This comprehensive safety framework reinforced public trust and regulatory confidence, making Leqembi one of the best-monitored Alzheimer’s therapies ever deployed at scale.
Impact on the Market
The commercial and clinical success of Leqembi in 2025 had a transformative impact on the global Alzheimer’s therapeutics market. For decades, Alzheimer’s research had been marred by high attrition rates, repeated clinical trial failures, and skepticism regarding the amyloid hypothesis. Biogen’s Leqembi, alongside Eli Lilly’s Donanemab, validated amyloid clearance as a viable disease-modifying approach, reigniting investor and research confidence in the field.
The therapy’s global rollout also stimulated new investments in next-generation Alzheimer’s drugs, including those targeting tau protein aggregation, neuroinflammation, and synaptic repair. Pharmaceutical firms such as Roche, AbbVie, and Novartis accelerated their late-stage clinical programs, inspired by Biogen’s commercial proof of concept.
In addition, healthcare systems began to adapt to the new therapeutic paradigm. Diagnostic innovation — including PET imaging, cerebrospinal fluid (CSF) biomarker testing, and blood-based diagnostics — experienced increased demand, as early detection became critical for effective Leqembi administration. This led to new partnerships between diagnostic firms and hospitals, indirectly driving growth across the broader neurodegenerative ecosystem.
Market analysts widely regarded Biogen’s success as a turning point in Alzheimer’s care, shifting the industry’s focus from symptomatic management to disease modification. The therapy’s availability in Asia-Pacific and Europe also supported regional growth in the Alzheimer’s market, which was projected to exceed USD 9 billion globally by 2026, with biologics accounting for over half of total revenue share.
Financial After Implementation
The commercial launch of Leqembi translated into strong financial performance for Biogen in FY2025. The company reported USD 1.1 billion in global sales from Leqembi, marking a substantial contribution to its neuroscience portfolio and establishing it as a cornerstone revenue driver alongside its multiple sclerosis franchise.
Biogen’s total revenue in FY2025 rose by 14% year-over-year, with Alzheimer’s therapeutics contributing nearly 20% of its total neuroscience sales. The firm also benefited from strategic cost optimization through Eisai’s manufacturing and distribution infrastructure, which reduced operational expenditure by approximately 8% compared to standalone logistics models.
Investor sentiment improved significantly, with Biogen’s share price appreciating over 25% during 2025, fueled by growing demand, reimbursement confidence, and global expansion prospects. Moreover, the success of Leqembi bolstered Biogen’s R&D pipeline, attracting fresh collaborations for next-generation combination therapies that target both amyloid and tau pathways.
Beyond financial metrics, Biogen’s real success lay in its social and healthcare impact. The company demonstrated that with the right scientific validation, regulatory alignment, and patient engagement, it was possible to turn one of medicine’s greatest challenges, Alzheimer’s, into a manageable condition with measurable outcomes.
Conclusion
Biogen had not only cemented its position as a global leader in Alzheimer’s therapeutics but also reshaped the trajectory of neurodegenerative disease management. The company’s success with Leqembi underscored the importance of innovation rooted in precision medicine, digital health integration, and patient safety.
Through its collaboration with Eisai, Biogen bridged the gap between groundbreaking science and real-world care, setting a new benchmark for how pharmaceutical companies can scale advanced biologics responsibly.
Leqembi’s journey — from clinical validation to global adoption — stands as a defining case study in the Alzheimer’s therapeutics market, exemplifying how scientific persistence, digital integration, and global collaboration can converge to deliver tangible hope for millions of patients and families affected by Alzheimer’s disease.
Dive into the full analysis here: https://www.precedenceresearch.com/alzheimer-therapeutics-market